124 related articles for article (PubMed ID: 12185285)
1. Absence of canine oral papillomavirus DNA following prophylactic L1 particle-mediated immunotherapeutic delivery vaccination.
Moore RA; Nicholls PK; Santos EB; Gough GW; Stanley MA
J Gen Virol; 2002 Sep; 83(Pt 9):2299-2301. PubMed ID: 12185285
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic immunisation with COPV early genes by epithelial DNA delivery.
Moore RA; Walcott S; White KL; Anderson DM; Jain S; Lloyd A; Topley P; Thomsen L; Gough GW; Stanley MA
Virology; 2003 Sep; 314(2):630-5. PubMed ID: 14554090
[TBL] [Abstract][Full Text] [Related]
3. Intraepithelial DNA immunisation with a plasmid encoding a codon optimised COPV E1 gene sequence, but not the wild-type gene sequence completely protects against mucosal challenge with infectious COPV in beagles.
Moore RA; Santos EB; Nicholls PK; White KL; Anderson DM; Lloyd A; Topley P; Romanos M; Thomsen L; Parmar V; Walcott S; Gough GW; Stanley MA
Virology; 2002 Dec; 304(2):451-9. PubMed ID: 12504584
[TBL] [Abstract][Full Text] [Related]
4. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs.
Stanley MA; Moore RA; Nicholls PK; Santos EB; Thomsen L; Parry N; Walcott S; Gough G
Vaccine; 2001 Apr; 19(20-22):2783-92. PubMed ID: 11282188
[TBL] [Abstract][Full Text] [Related]
5. Cell-mediated immune responses to COPV early proteins.
Jain S; Moore RA; Anderson DM; Gough GW; Stanley MA
Virology; 2006 Dec 5-20; 356(1-2):23-34. PubMed ID: 16949120
[TBL] [Abstract][Full Text] [Related]
6. Protection of beagle dogs from mucosal challenge with canine oral papillomavirus by immunization with recombinant adenoviruses expressing codon-optimized early genes.
Johnston KB; Monteiro JM; Schultz LD; Chen L; Wang F; Ausensi VA; Dell EC; Santos EB; Moore RA; Palker TJ; Stanley MA; Jansen KU
Virology; 2005 Jun; 336(2):208-18. PubMed ID: 15892962
[TBL] [Abstract][Full Text] [Related]
7. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
Suzich JA; Ghim SJ; Palmer-Hill FJ; White WI; Tamura JK; Bell JA; Newsome JA; Jenson AB; Schlegel R
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11553-7. PubMed ID: 8524802
[TBL] [Abstract][Full Text] [Related]
8. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.
Berg M; Difatta J; Hoiczyk E; Schlegel R; Ketner G
Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4590-5. PubMed ID: 15767581
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection.
Nicholls PK; Klaunberg BA; Moore RA; Santos EB; Parry NR; Gough GW; Stanley MA
Virology; 1999 Dec; 265(2):365-74. PubMed ID: 10600607
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
[TBL] [Abstract][Full Text] [Related]
11. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
Ghim S; Newsome J; Bell J; Sundberg JP; Schlegel R; Jenson AB
Exp Mol Pathol; 2000 Jun; 68(3):147-51. PubMed ID: 10816383
[TBL] [Abstract][Full Text] [Related]
12. A formalin-inactivated vaccine protects against mucosal papillomavirus infection: a canine model.
Bell JA; Sundberg JP; Ghim SJ; Newsome J; Jenson AB; Schlegel R
Pathobiology; 1994; 62(4):194-8. PubMed ID: 7734063
[TBL] [Abstract][Full Text] [Related]
13. Detection of canine oral papillomavirus-DNA in canine oral squamous cell carcinomas and p53 overexpressing skin papillomas of the dog using the polymerase chain reaction and non-radioactive in situ hybridization.
Teifke JP; Löhr CV; Shirasawa H
Vet Microbiol; 1998 Feb; 60(2-4):119-30. PubMed ID: 9646444
[TBL] [Abstract][Full Text] [Related]
14. Detection of viral DNA and E4 protein in basal keratinocytes of experimental canine oral papillomavirus lesions.
Nicholls PK; Doorbar J; Moore RA; Peh W; Anderson DM; Stanley MA
Virology; 2001 May; 284(1):82-98. PubMed ID: 11352670
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of human papillomaviruses in the normal oral cavity of adults.
Terai M; Hashimoto K; Yoda K; Sata T
Oral Microbiol Immunol; 1999 Aug; 14(4):201-5. PubMed ID: 10551162
[TBL] [Abstract][Full Text] [Related]
16. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
17. Applications of biotechnology to human-papillomavirus-induced diseases.
Faras AJ; Pass F
Clin Dermatol; 1985; 3(4):200-3. PubMed ID: 2850858
[No Abstract] [Full Text] [Related]
18. Molecular characteristics of cutaneous papillomavirus from the canine pigmented epidermal nevus.
Tanabe C; Kano R; Nagata M; Nakamura Y; Watanabe S; Hasegawa A
J Vet Med Sci; 2000 Nov; 62(11):1189-92. PubMed ID: 11129863
[TBL] [Abstract][Full Text] [Related]
19. Cloning and characterization of a canine oral papillomavirus.
Sundberg JP; O'Banion MK; Schmidt-Didier E; Reichmann ME
Am J Vet Res; 1986 May; 47(5):1142-4. PubMed ID: 3013052
[TBL] [Abstract][Full Text] [Related]
20. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
